A continually updated, attorney-reviewed reference to every US state with statutory authority, Right-to-Try inclusion, or disclosure framework for adult stem cell procedures. Current through April 2026.
Explicit statutory authority for physician-administered investigational stem cell procedures.
Tier 1 — Open Practice State
Under Florida's 2025 Stem Cell Therapy Act, licensed physicians may legally market and administer stem cell therapies that are not yet FDA-approved, provided the treatment is for orthopedic conditions, wound care, or pain management and the cells are sourced from FDA-registered, accredited facilities.
Tier 1 — Open Practice State
Texas was the first state to formally authorize investigational adult stem cell therapies for patients with severe chronic diseases or terminal illness who have exhausted conventional treatment options.
Tier 1 — Open Practice State
Utah's Right-to-Try statute permits investigational treatment for terminal illness, and the 2024 SB 199 amendment requires healthcare providers to give patients written notice and obtain signed consent before performing any stem cell therapy not approved by the FDA.
Tier 1 — Open Practice State
Wyoming's Stem Cell Freedom Act of 2026 establishes a state framework empowering physicians and patients to access stem cell therapies.
Tier 1 — Open Practice State
Tennessee's HB 2246 authorizes Tennessee-licensed physicians to administer stem cell and regenerative cellular therapies that are not yet FDA-approved for orthopedic, pain management, and wound-care indications, provided cells are sourced from FDA-registered, accredited establishments and patients sign an informed-consent disclosure.
Investigational access for severe chronic or terminal illness.
Tier 2 — Right-to-Try Includes Stem Cells
Alabama law allows investigational adult stem cell therapies for patients with severe chronic or terminal diseases after exhausting other treatment options, with informed consent and IRB oversight.
Tier 2 — Right-to-Try Includes Stem Cells
Mississippi expanded its Right-to-Try statute in 2020 to include adult mesenchymal stem cells (MSCs) extracted from bone marrow, indicated for debilitating disability, traumatic injury, or terminal illness with mandatory written informed consent.
Tier 2 — Right-to-Try Includes Stem Cells
Arkansas's Right-to-Try statute permits access to investigational treatments for patients with terminal illness and notably does not carve out an exclusion for stem cell-derived therapies, leaving access available under the standard Right-to-Try framework.
Practice permitted; FDA-status disclosure mandated.
Tier 3 — Practice Permitted with Disclosure
California requires healthcare providers to alert patients that stem cell interventions they receive are not FDA-approved, and SB 1495 modified informed consent requirements while mandating annual reporting by the Medical Board.
Tier 3 — Practice Permitted with Disclosure
Vermont's Act 61 provides statutory definitions for stem cell-related products and requires practitioners administering FDA-unapproved therapies to issue a standardized patient notice, obtain signed informed consent, and disclose FDA non-approval status in any related advertisement.
Tier 3 — Practice Permitted with Disclosure
Washington law requires providers to alert patients that the stem cell interventions they are receiving are not FDA-approved and to obtain documented informed consent prior to treatment.
A patient navigator will review your information and, if your situation appears appropriate, refer you to a state-licensed physician in one of the framework states for an independent consultation. Typically within one business day.